CA3246231A1 - Dérivés de tryptamine substitués par c4-carbonothioate et procédés d'utilisation - Google Patents
Dérivés de tryptamine substitués par c4-carbonothioate et procédés d'utilisationInfo
- Publication number
- CA3246231A1 CA3246231A1 CA3246231A CA3246231A CA3246231A1 CA 3246231 A1 CA3246231 A1 CA 3246231A1 CA 3246231 A CA3246231 A CA 3246231A CA 3246231 A CA3246231 A CA 3246231A CA 3246231 A1 CA3246231 A1 CA 3246231A1
- Authority
- CA
- Canada
- Prior art keywords
- receptor
- chemical
- compound
- pct
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La divulgation concerne de nouveaux composés dérivés de tryptamine substitués par C4-carbonothioate et des formulations pharmaceutiques et récréatives les contenant. Les formulations pharmaceutiques peuvent être utilisées pour traiter des troubles neurologiques cérébraux.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263321440P | 2022-03-18 | 2022-03-18 | |
| US63/321,440 | 2022-03-18 | ||
| US202263347835P | 2022-06-01 | 2022-06-01 | |
| US63/347,835 | 2022-06-01 | ||
| PCT/CA2022/051266 WO2023173197A1 (fr) | 2022-03-18 | 2022-08-22 | Dérivés de tryptamine substitués par c4-carbonothioate et procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246231A1 true CA3246231A1 (fr) | 2023-09-21 |
Family
ID=93294636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246231A Pending CA3246231A1 (fr) | 2022-03-18 | 2022-08-22 | Dérivés de tryptamine substitués par c4-carbonothioate et procédés d'utilisation |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250206701A1 (fr) |
| EP (1) | EP4493542A1 (fr) |
| JP (1) | JP2025510666A (fr) |
| AU (1) | AU2022447256A1 (fr) |
| CA (1) | CA3246231A1 (fr) |
-
2022
- 2022-08-22 AU AU2022447256A patent/AU2022447256A1/en active Pending
- 2022-08-22 JP JP2024555281A patent/JP2025510666A/ja active Pending
- 2022-08-22 US US18/848,351 patent/US20250206701A1/en active Pending
- 2022-08-22 EP EP22931275.6A patent/EP4493542A1/fr active Pending
- 2022-08-22 CA CA3246231A patent/CA3246231A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4493542A1 (fr) | 2025-01-22 |
| US20250206701A1 (en) | 2025-06-26 |
| AU2022447256A1 (en) | 2024-11-07 |
| JP2025510666A (ja) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250205197A1 (en) | Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using | |
| JP5437473B2 (ja) | Ａｍｐａ及びｎｍｄａ受容体モジュレーターとして使用するベンゾチアジアゼピン誘導体 | |
| US11707447B1 (en) | C4-carbonothioate-substituted tryptamine derivatives and methods of using | |
| EP3303323B1 (fr) | Composés hétérocycliques 3,3-difluoropipéridine carbamate utilisés en tant qu'antagonistes des récepteurs nmda nr2b | |
| US20230398097A1 (en) | Carboxylated psilocybin derivatives and methods of using | |
| CA2187429A1 (fr) | Derive de n-(3-pyrrolidinyl)benzamide | |
| TW200304817A (en) | Chemical compounds | |
| CN111205291B (zh) | 三唑并环类化合物、其制备方法、中间体和应用 | |
| US11945778B2 (en) | C4-carbonothioate-substituted tryptamine derivatives and methods of using | |
| US20250206701A1 (en) | C4-carbonothioate-substituted tryptamine derivatives and methods of using | |
| US20250197351A1 (en) | C4-carboxylic acid-substituted tryptamine derivatives and methods of using | |
| US7662750B2 (en) | Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds | |
| US12338231B1 (en) | N-heterocycle substituted tryptamine derivatives and methods of using | |
| US12195439B1 (en) | C1-substituted isopropylamine fused heterocyclic mescaline derivatives | |
| WO2024186579A1 (fr) | Inhibiteurs de protéine kinase et leurs utilisations |